Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids.

Peter P. Toth, Thomas D. Dayspring, Gregory S. Pokrywka

Research output: Contribution to journalArticle

Abstract

The reduction of low-density lipoprotein cholesterol in patients at risk for acute cardiovascular events is the cornerstone of lipid management in both the primary and secondary prevention settings. Serum triglyceride levels exceeding 150 mg/dL are abnormal and confer increased risk for developing coronary artery disease in both men and women. Serum triglycerides are derived from both dietary and endogenous biosynthetic pathways. Triglyceride metabolism has a complex regulatory circuitry and intimately impacts the production and disposal of multiple lipoprotein species. Hypertriglyceridemia is highly prevalent and is associated with multiple forms of dyslipidemia but tends to be undertreated. Therapeutic intervention with fibric acid derivatives and omega-3 fish oils is associated with significant reductions in both fasting and postprandial serum triglyceride concentrations. A variety of prospective, placebo-controlled clinical trials have also shown that these agents significantly impact risk for multiple cardiovascular end points.

Original languageEnglish (US)
Pages (from-to)71-79
Number of pages9
JournalCurrent atherosclerosis reports
Volume11
Issue number1
DOIs
StatePublished - Jan 2009

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids.'. Together they form a unique fingerprint.

  • Cite this